Shaoguang Li

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5334971/publications.pdf

Version: 2024-02-01

43	892	687363 13	477307 29
papers	citations	h-index	g-index

43	43	43	1561
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Leukemogenic Chromatin Alterations Promote AML Leukemia Stem Cells via a KDM4C-ALKBH5-AXL Signaling Axis. Cell Stem Cell, 2020, 27, 81-97.e8.	11.1	140
2	A therapeutically targetable mechanism of BCR-ABLâ€“independent imatinib resistance in chronic myeloid leukemia. Science Translational Medicine, 2014, 6, 252ra121.	12.4	105
3	Leukemic marrow infiltration reveals a novel role for Egr3 as a potent inhibitor of normal hematopoietic stem cell proliferation. Blood, 2015, 126, 1302-1313.	1.4	93
4	YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner. Blood, 2021, 138, 71-85.	1.4	87
5	Chronic Myelogenous Leukemiaâ€“ Initiating Cells Require Polycomb Group Protein EZH2. Cancer Discovery, 2016, 6, 1237-1247.	9.4	72
6	Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine. Blood, 2017, 130, 655-665.	1.4	63
7	A deep learning diagnostic platform for diffuse large B-cell lymphoma with high accuracy across multiple hospitals. Nature Communications, 2020, 11, 6004.	12.8	51
8	Differential m6A RNA landscapes across hematopoiesis reveal a role for IGF2BP2 in preserving hematopoietic stem cell function. Cell Stem Cell, 2022, 29, 149-159.e7.	11.1	49
9	Survival regulation of leukemia stem cells. Cellular and Molecular Life Sciences, 2016, 73, 1039-1050.	5.4	31
10	Novel oral transforming growth factorâ€î² signaling inhibitor <scp>EW</scp>â€7197 eradicates <scp>CML</scp>â€initiating cells. Cancer Science, 2016, 107, 140-148.	3.9	28
11	Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1. Blood, 2016, 127, 1803-1813.	1.4	24
12	PKC Pathways Mediate BCR-ABL-Independent Imatinib Resistance in Chronic Myeloid Leukemia. Blood, 2014, 124, 1790-1790.	1.4	21
13	The Src kinases Hck, Fgr, and Lyn activate Abl2/Arg to facilitate IgG-mediated phagocytosis andLeishmaniainfection. Journal of Cell Science, 2016, 129, 3130-43.	2.0	18
14	Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy. Blood, 2016, 127, 1912-1922.	1.4	15
15	Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia. OncoTargets and Therapy, 2014, 7, 177.	2.0	14
16	Chronic Myeloid Leukemia (CML) Mouse Model in Translational Research. Methods in Molecular Biology, 2016, 1438, 225-243.	0.9	12
17	An artificial intelligence deep learning platform achieves high diagnostic accuracy for Covid-19 pneumonia by reading chest X-ray images. IScience, 2022, 25, 104031.	4.1	11
18	Alox5 Blockade Eradicates JAK2V617F-Induced Polycythemia Vera in Mice. Cancer Research, 2017, 77, 164-174.	0.9	10

#	Article	IF	Citations
19	Prosurvival kinase PIM2 is a therapeutic target for eradication of chronic myeloid leukemia stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10482-10487.	7.1	10
20	Therapeutic inhibition of FcÎ³RIIb signaling targets leukemic stem cells in chronic myeloid leukemia. Leukemia, 2020, 34, 2635-2647.	7.2	8
21	Leukemia Stem Cells in Chronic Myeloid Leukemia. Advances in Experimental Medicine and Biology, 2019, 1143, 191-215.	1.6	7
22	Without GABP Transcription Factor, BCR-ABL Cannot Transform HSCs to Leukemic Stem Cells Nor Induce Chronic Myelogenous Leukemia in Mice. Blood, 2011, 118, 965-965.	1.4	7
23	Concise Review: Exploiting Unique Biological Features of Leukemia Stem Cells for Therapeutic Benefit. Stem Cells Translational Medicine, 2019, 8, 768-774.	3.3	5
24	Induction of Chronic Myeloid Leukemia in Mice. Methods in Molecular Biology, 2016, 1465, 17-25.	0.9	4
25	The Scd1 Gene Functions as a Tumor Suppressor In Leukemia Stem Cells. Blood, 2010, 116, 201-201.	1.4	3
26	Good Tolerance and Durable Remission for Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Refractory/Relapsed Mantle Cell Lymphoma. Blood, 2019, 134, 2818-2818.	1.4	1
27	Genetic Depletion of Fc Gamma Receptor 2b Affects CML Stem Cell Biology. Blood, 2014, 124, 4528-4528.	1.4	1
28	Eradication of Chronic Myelogenous Leukemia By Inactivation of the Polycomb Group Protein EZH2. Blood, 2014, 124, 778-778.	1.4	1
29	DNA Microarray Assay Helps to Identify Functional Genes Specific for Leukemia Stem Cells. Dataset Papers in Science, 2013, 2013, 1-5.	1.0	1
30	Management and orphan drug development for acute myeloid leukemia. Expert Opinion on Orphan Drugs, 2014, 2, 441-451.	0.8	0
31	Fighting fat in AML. Blood, 2016, 128, 1910-1911.	1.4	0
32	Beta-catenin Is Essential for Survival of Leukemia Stem Cells Insensitive to Kinase Inhibition in Mice with BCR-ABL Induced Chronic Myeloid Leukemia.. Blood, 2008, 112, 1080-1080.	1.4	0
33	Distinct Gab2-Mediated Signaling Pathways Are Essential for Myeloid or Lymphoid Transformation and Leukemogenesis by BCR-ABL. Blood, 2008, 112, 570-570.	1.4	0
34	The Tumor Suppressor Role of the Msr1 Gene in Cancer Stem Cells of Chronic Myeloid Leukemia.. Blood, 2009, 114, 188-188.	1.4	0
35	HIF1Î± Is Required for Survival Maintenance of Chronic Myeloid Leukemia Stem Cells. Blood, 2011, 118, 449-449.	1.4	0
36	PRKD2 Serine-Threonine Kinase, an Essential Effector of Gabp Transcription Factor, Is Required for Development of Chronic Myelogenous Leukemia. Blood, 2012, 120, 1672-1672.	1.4	0

#	Article	IF	Citations
37	Nfkb1 Plays a Tumor-Suppressing Role in BCR-ABL-Induced Leukemias. Blood, 2012, 120, 1666-1666.	1.4	0
38	Timing of the Loss of Pten Is Critical in Determining the Disease Phenotype in Mice- a Mouse Model for Pediatric Mixed MDS/MPN. Blood, 2014, 124, 3585-3585.	1.4	0
39	Targeting Chronic Myeloid Leukemia Stem Cells through Pharmacological Inhibition of HIF-1Î±. Blood, 2016, 128, 4235-4235.	1.4	0
40	Inhibition of CML Stem Cells with an Alkaloid That Reduces Î²-Catenin. Blood, 2016, 128, 1882-1882.	1.4	0
41	Activation of JAK2/STAT5 Pathway Reduces Expression Level of DNMT3a in MPN Cell Line. Blood, 2019, 134, 5394-5394.	1.4	0
42	Patients with Bone and Bone Marrow Involvement Had Better OS and PFS in Patients with Aggressive Non-Hodgkin Lymphoma Treated with CD19 CAR T Cells. Blood, 2019, 134, 5315-5315.	1.4	0
43	Clinical Presentation, Management and Biomarkers of Cytokine Release Syndrome after Anti-CD19 CART-Cell Therapy for r/r ALL. Blood, 2019, 134, 5625-5625.	1.4	0